HTLV-1 is a global infection with 5-20 million infected individuals. Although only a minority of
infected individuals develop myelopathy, lymphoproliferative malignancy, or inflammatory …

The COVID-19 pandemic response has shown how vaccine platform technologies can be
used to rapidly and effectively counteract a novel emerging infectious disease. The speed of …

Human T‐lymphotropic virus type‐1 (HTLV‐1) was the first discovered human oncogenic
retrovirus, the etiological agent of two serious diseases have been identified as adult T‐cell …

Various chemical adjuvants are available to augment immune responses to non-replicative,
subunit vaccines. Optimized adjuvant selection can ensure that vaccine-induced immune …

The H5N1 subtype highly pathogenic avian influenza virus (HPAIV) reveals high variability
and threatens poultry production and public health. To prevent the spread of H5N1 HPAIV …

The vast majority of seasonal influenza vaccines administered each year are derived from
virus propagated in eggs using technology that has changed little since the 1930s. The …

Robust and precise tools are needed to enhance the functionality and resilience of synthetic
nanoarchitectures. Here, we have employed directed evolution and rational design to build …

Modern scientific instruments are becoming essential for discoveries because they provide
unprecedented insight into physical or biological events–often in real time. However, these …

Koalas are of great cultural, ecological and economic significance to Australia. However,
they are in steep decline throughout much of their geographic range, with the recently …

The need for rapid response vaccines and therapeutics to counter emerging viral diseases
has been highlighted by the ongoing COVID-19 pandemic. The University of Queensland …